For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

Pulmocide Ltd., (“the Company”), a late-stage biopharmaceutical company developing inhaled opelconazole for patients suffering from serious acute and chronic respiratory diseases, today announced that ...

Researchers from POSTECH and Kyungpook National University have developed a novel inhalable therapeutic delivery system for ...

For individuals with chronic lung conditions, the winter season and the current cold snap poses significant challenges. We ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.